Hot Sector and Opportunity in a Psychedelic Biopharma Enterprise with a Focus Toward New Science, Shareholder Value and Recently Announced Plans to Up-list to the NASDAQ

Hot Sector and Opportunity in a Psychedelic Biopharma Enterprise with a Focus Toward New Science, Shareholder Value and Recently Announced Plans to Up-list to the NASDAQ

Under the radar, low float with patented psilocybin treatments. Silo Pharma (OTCQB: SILO) heads are turning with names like Pfizer (PFE), Eli Lilly (LLY) and GlaxoSmithKline (GSK) entering this space. Expect some M&A within this sector soon. Patented tech is key.

Science and commerce are looking at psychedelic substances such as psilocybin, LSD, Ketamine and MDMA and to treat many of the same neurological disorders that cannabis does and so much more.

 

Silo Pharma Inc. (OTCQB: SILO)

Silo Pharma is one the few biotech’s we have come across with university collaborations and patented technology for treatments with psilocybin!

Silo’s goal is to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.

 

Opportunities to invest in companies developing new technologies usually come too late. They come to our attention after a significant catalyst has already moved the price significantly higher and we find ourselves wishing we’d have gotten in while the shares were cheap. SILO is a company with shares that are still affordable, and we’ve laid out the reasons that might change soon below.

 

SILO has assembled a team of scientific advisors to ensure they are looking at viable projects and they have the available capital to finance them through the full term of development.

 

It wasn’t that long ago that developing biopharma treatments with cannabis derivatives was theoretical, and start-ups were cheap to invest in. A lot of fortunes have been made in the cannabis sector since.

 

Merging traditional therapeutics with psychedelic research.

Shrooms psilocybin 

 

Recent Developments and News

 

On July 7, 2021, SILO announced they extended their agreement for experimental Rheumatoid Arthritis nanoparticle homing peptide. Eric Weisblum, Chairman and CEO of Silo Pharma stated, “The ability to deliver traditional therapeutics, psilocybin or other psychedelic drugs directly to targeted areas of the body with this technology could be revolutionary by increasing the efficacy of the treatment while reducing toxicity and the amount of medication needed.”

 

SILO has entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This SRA, just negotiated in June 2021, will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain.

 

On October 19, 2020, SILO was approved for trading on the OTCQB Venture Market, an upgrade from the pink sheets. On May 25, 2021, the company announced that it has submitted its initial application to list on the NASDAQ Capital Market.

 

Also in May 2021, the company announced that its investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review in the Netherlands. Eric Weisblum, CEO of Silo Pharma stated, “We are pleased to have reached this milestone and look forward to sharing further information on this study with the scientific community and our shareholders.”

 

Let’s look at the programs that SILO is involved with:

 

Investigator Lead sponsored study with Maastricht University, which utilizes repeated low doses of LSD and Psilocybin effects on cognitive and emotional dysfunction in Parkinson’s disease and to understand its mechanism of action. The investigator is completing acquiring the substances for the study and will then finalize the documentation to submit to the Ethics committee.

Silo Pharma, Inc. enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis. “Joint-homing peptides for use in the investigation and treatment of arthritogenic processes” novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.

Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS. An innovative Central nervous system-homing peptides for treatment of multiple sclerosis and other neuroinflammatory pathology, signing a Master License Agreement with the University of Maryland Baltimore.

Silo Pharma Entered into a Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

 

Silo Pharma receives $1M in up front licensing deal for its Psilocybin cancer therapeutic applications. In consideration for granting the license, Silo Pharma received a one-time cash payment of $500,000 and shares of newly designated Convertible Preferred Stock valued at $500,000 on the date of execution of the license. Silo Pharma will also be entitled to potential royalty payments on Net Sales (as defined in the Agreement) if the licensed property is commercially developed.​

 

Silo Pharma entered, completes, and grants a sub license agreement for the treatment of pain from neuroinflammation in cancer patients.

 

​Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics.

 

With a current market value under $25M, SILO looks to be under the radar of a lot of biopharma investors. With an up-list to the NASDAQ pending SILO could quickly become well known and of course the market value could soar. A cursory look at development stage biopharma NASDAQ stocks will result in a plethora of companies valued in the hundreds of millions of dollars.

 

SILO already has collaborations with universities to develop leading edge science and innovative therapies for some of the hardest to treat indications. The combination of psychedelic compounds with existing and newly developed therapies is a novel approach to new treatments and SILO is at the forefront of these developments.

 

Let’s look at the SILO Intellectual Property portfolio:

 

U.S. Provisional Patent Application No. 63/060,573, titled “Central Nervous System Delivery of Psilocybin,” filed August 3, 2020.

 

U.S. Provisional Patent Application No. 63/060,569, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin,” filed August 3, 2020.

 

U.S. Provisional Patent Application No. 63/060,577, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin,” filed August 3, 2020.

U.S. Provisional Patent Application No. 63/24,827, titled “Use of Psilocybin in Cancer Treatment,” filed December 13, 2020.

 

The psychedelics sector is growing rapidly with many public companies already established and IPOs for others already planned. SILO happens to be several steps ahead of the pack with several patents pending, university collaborations and capital available for development. Its important to note that SILO is looking beyond depressive disorders and working to develop treatments for other indications.

 

Author and PhD, Joshua Cohen published an article on July 5, 2021, in Forbes titled “Psychedelic Drugs Are Moving from The Fringes of Medicine to the Mainstream”. His insights into the sector are invaluable and he discusses the FDA relationship with psychedelic compounds. It’s a great read for anyone with a current interest in this field of medicine.

 

SILO appears to be a value compared to its peers in the psychedelic sector (development stage, absent revenue):

 

Seelos Therapeutics, Inc. (SEEL)           Market value – $270M

Mind Medicine Inc. (MNMD)                Market value – $805M

COMPASS Pathways plc (CMPS)           Market value – $1.5B

Silo Pharma, Inc. (SILO)                           Market value – $21M

 

Silo Pharma Inc’s CEO and Founder, Eric Weisblum, has over 25 years of Wall Street experience most recently in the biotechnology sector. Eric served on the board of directors of Aikido Pharma (AIKI), a Nasdaq-listed biotech company focused on the commercialization of oncology therapeutics where he advised on the operations and licensing of their technology. Prior to Aikido, he was the President of Sableridge Capital.

 

Do your due diligence on SILO and determine if you think the company shares might reward you handsomely in the future.

 

Silo Pharma, Inc.

Englewood Cliffs, NJ 07632

https://silopharma.com/

 

The Traders News Group and Lucky’s Breakout Stocks

 

Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
https://tradersnewssource.com/cookie-policy-us/
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Editor@TradersNewsSource.com
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated ten thousand dollars cash via bank wire for our distributed opinions this week on silo. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.

Tagged with